8-K: Relmada Therapeutics Reports Q2 2026 Results, Advances Drug Pipeline

Relmada Therapeutics announced its second quarter 2026 financial results, highlighting progress in advancing NDV-01 and sepranolone toward IND filings by year-end 2026, supported by a robust cash balance extending operations through 2029.

Summary

• Relmada Therapeutics reported its financial results for the second quarter ended June 30, 2026.
• The company is advancing its drug candidates, NDV-01 and sepranolone, with IND filings expected by the end of 2026.
• NDV-01 is progressing towards a Phase 3 registrational program (RESCUE) upon IND clearance for non-muscle invasive bladder cancer (NMIBC).
• Sepranolone is also on track for an IND filing by year-end 2026, with a Phase 2 proof-of-concept study planned for Prader-Willi Syndrome.
• The company strengthened its leadership team with the appointment of Bipin Dalmia as Chief Business Officer.
• Relmada was added to the Russell 2000 and Russell 3000 Indexes.
• As of June 30, 2026, the company had a cash balance of $217.7 million, which is expected to fund operations through 2029.
• Research and development expenses increased to $8.4 million for Q2 2026 from $2.8 million in Q2 2025, primarily due to increased study and manufacturing costs for NDV-01 and sepranolone.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, with significant progress on key drug development milestones and a strong cash position providing ample runway.

Positives

• Strong cash position of $217.7 million as of June 30, 2026, sufficient to fund operations through 2029, including the NDV-01 Phase 3 program.
• Advancement of both NDV-01 and sepranolone towards IND filings by year-end 2026.
• FDA alignment on registrational development pathways for NDV-01.
• Successful addition to the Russell 2000 and Russell 3000 Indexes.
• Strengthened leadership with the appointment of Bipin Dalmia as Chief Business Officer.
• Positive Phase 2a data for NDV-01 in high-risk NMIBC patients, showing a 95% anytime Complete Response (CR) rate.
• Sepranolone has positive proof-of-concept data and a differentiated mechanism of action for compulsivity disorders.
• NDV-01's potential to become a next-generation standard-of-care in NMIBC due to its ease of administration and sustained drug release.

Negatives

• Net loss for the three months ended June 30, 2026, was $12.9 million, or $0.11 per share, compared to a net loss of $9.9 million, or $0.30 per share, in the prior year period.
• Research and development expenses significantly increased to $8.4 million in Q2 2026 from $2.8 million in Q2 2025.
• Net cash used in operating activities increased to $9.6 million for Q2 2026 from $6.4 million in Q2 2025.
• The company has not yet achieved profitability, with an accumulated deficit of $730.2 million as of June 30, 2026.

Risks

• Potential for product candidates to fail to progress in development.
• Clinical trials may fail to demonstrate statistically or clinically significant efficacy and/or safety.
• Failure to secure FDA agreement on regulatory paths for NDV-01 and sepranolone.
• Challenges in executing manufacturing and CMC activities, including GMP manufacturing and scale-up.
• Failure to secure adequate drug supply for NDV-01 and sepranolone.
• Patent applications may not result in issued patents or may be challenged.
• Uncertainties in estimating cash runway and future expenses.
• The NMIBC market is competitive with existing and emerging therapies.

Future Outlook

The company expects to file INDs for both NDV-01 and sepranolone by the end of 2026. Upon IND clearance, Relmada plans to initiate the Phase 3 RESCUE registrational program for NDV-01 and a Phase 2 proof-of-concept study for sepranolone in Prader-Willi Syndrome. The current cash balance is projected to fund operations through 2029, including the completion of the NDV-01 Phase 3 program.

Management Comments

• "Relmada has entered a critical execution phase as we prepare NDV-01 for registrational development. With FDA alignment, a robust clinical dataset, an experienced leadership team, and capital expected to fund operations through completion of the Phase 3 RESCUE program, we believe the Company is well positioned to create significant long-term value."
• "Our immediate priority is manufacturing execution for NDV-01. Bringing a novel, sustained-release therapy of this kind into registrational development requires careful execution, and we are focused on completing the remaining activities needed to support the IND filing."
• "Since joining Relmada, I have become increasingly convinced that NDV-01 represents one of the most compelling opportunities in NMIBC. As the NMIBC treatment landscape continues to evolve, patients and physicians are seeking therapies that deliver meaningful efficacy and durability without compromising convenience, tolerability, or ease of use. As we advance toward registrational development, NDV-01s highly differentiated profile and potential applicability across multiple patient populations position it to become a foundational and best-in-class intravesical therapy across the NMIBC disease spectrum."

Industry Context

StockSavvy.ai notes that Relmada Therapeutics is operating in the competitive oncology and central nervous system disorder therapeutic areas. The company's focus on non-muscle invasive bladder cancer (NMIBC) addresses a significant market with high recurrence rates and unmet needs, particularly for high-risk and BCG-unresponsive patients. The advancement of NDV-01 aligns with industry trends towards developing more targeted and sustained-release therapies to improve efficacy and patient convenience.

Comparison to Industry Standards

• The development of NDV-01, a sustained-release intravesical formulation of gemcitabine and docetaxel, aims to improve upon conventional intravesical chemotherapies like BCG, mitomycin-C, and standard gemcitabine/docetaxel regimens, which often have high recurrence rates and require frequent administration.
• NDV-01's proposed administration time of under 5 minutes and office-based delivery contrasts with more complex or time-consuming treatments, positioning it favorably for adoption.
• The Phase 3 RESCUE program for NDV-01 is designed with two distinct registrational pathways targeting different NMIBC patient populations (BCG-unresponsive and intermediate-risk), a common strategy for maximizing market penetration.
• Sepranolone's development for Prader-Willi Syndrome targets a rare genetic disorder where current treatments focus on symptom management rather than modifying underlying pathology, indicating a potential first-in-class opportunity.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value if drug development milestones are met, reflected in stock performance and future market opportunities. The company's strong cash position provides operational stability.
• Patients: Potential access to novel therapies for NMIBC and Prader-Willi Syndrome with improved efficacy, safety, or convenience.
• Healthcare Providers: Introduction of new treatment options that may offer better patient outcomes and ease of administration.
• Employees: Continued employment and potential growth opportunities within a progressing clinical-stage company.

Next Steps

• Submit IND for NDV-01 by year-end 2026.
• Initiate Phase 3 RESCUE registrational program for NDV-01 upon IND clearance.
• Submit IND for sepranolone by year-end 2026.
• Initiate Phase 2 proof-of-concept study for sepranolone in Prader-Willi Syndrome upon IND clearance.
• Continue manufacturing and CMC activities for both NDV-01 and sepranolone.
• Conduct conference call and audio webcast to discuss corporate update and financial results.

Key Dates

Recommendation

The company is making significant progress with its pipeline and has a strong cash position, which are positive indicators. However, the increased R&D expenses and continued net losses, coupled with the inherent risks of drug development, warrant a cautious approach. The upcoming IND filings and initiation of Phase 3 trials are key catalysts, but the long road to potential approval and commercialization suggests a 'hold' rating until further de-risking events occur.

Keywords

NMIBC, NDV-01, bladder cancer, gemcitabine, docetaxel, sepranolone, Prader-Willi Syndrome, oncology